The effects of adrenaline, metaraminol, ephedrine and phenylephrine on myocardial irritability were evaluated in dogs at equivalent levels of isoflurane and halothane anaesthesia. The incidence of premature ventricular contractions associated with adrenaline and metaraminol infusions was significantly less during isoflurane anaesthesia, as compared with halothane. Ephedrine produced arrhythmias in approximately 50% of animals studied with both anaesthetics. Doses of adrenaline, metaraminol, and phenylephrine necessary to cause arrhythmias were greater during isoflurane anaesthesia. In addition, arrhythmias occurred at lower mean arterial pressures in all drug groups with halothane than with isoflurane anaesthesia.
The association of adrenaline-induced arrhythmias with the use of certain anaesthetic agents has received extensive study (Price, 1966; Katz and Epstein, 1968) . The occurrence of arrhythmias during anaesthesia may be related both to myocardial and peripheral drug actions at adrenergic receptor sites, and to the resultant effects of elevated arterial pressure and heart rate (Dresel, MacCannell and Nickerson, 1960; Riker et al., 1955) . Joas and Stevens (1971) found that adrenaline produced fewer arrhythmias in dogs anaesthetized with isoflurane (Forane) than at equivalent levels of halothane anaesthesia. However, adrenaline represents only one sympathomimetic amine used during the care of anaesthetized patients. Many other vasopressors which produce varying gradations of alpha-and beta-adrenergic stimulation may be administered for the treatment of systemic hypotension during clinical anaesthesia. While these drugs have not received a comparative evaluation, a few reports indicate that myocardial irritability during halothane anaesthesia may be affected by other sympathomimetic agents (Katz and Epstein, 1968; Orth et al., 1939; Catenacci et al., 1963) . Therefore, we have evaluated the effects of adrenaline, metaraminol, ephedrine, and phenylephrine on myocardial irritability and circulatory responses during isoflurane anaesthesia in dogs. For comparison, similar studies were performed at equivalent levels of halothane anaesthesia. 
METHODS
Seventy-seven experiments were performed on 21 male, mongrel dogs, with a mean weight of 16.0 kg (range 11.2-20.6 kg). Anaesthesia was induced and maintained in each dog with either isoflurane or halothane in oxygen. The animals received no drugs prior to study, and tracheal intubation was performed with a cuffed tube without the use of muscle relaxants. Ventilation was controlled with a volumelimited ventilator, and end-tidal carbon dioxide concentration was maintained at approximately 4% as determined with a Godart capnograph. A femoral artery and forelimb vein were cannulated percutaneously. Phasic and mean arterial pressures (MAP) were monitored with Statham P23DC transducers and were recorded on a Gilson polygraph. Oesophageal temperatures were measured with a thermistor probe and maintained at 37(±1)°C. Cardiac rhythm was recorded from lead II of the electrocardiogram. Before and during each experiment arterial Po 2 , Pco 2 , and pH were measured with a Radiometer BMS3 blood-gas analyser. Inspired and end-tidal anaesthetic concentrations were monitored with a Beckman LB-2 infrared halothane analyser. The instrument, which is also sensitive to isoflurane, was calibrated using gas mixtures stored in cylinders. The composition of these mixtures was determined by gas chromatography (Tham, Hardy and Shah, 1972) . Calibrations were performed in the presence of carbon dioxide to eliminate the crossover effect of this gas.
After induction of anaesthesia, inspired anaes- (Eger et al., 1965) and 1.48% for isoflurane (Joas and Stevens, 1971) . When the anaesthetic level had been established for a period ranging from 15 to 30 min, an arterial blood sample was obtained for the determination of Pa C o 2 and pHa. If the calculated base deficit (Andersen and Engel, 1960) was greater than 4 m.equiv/1. an appropriate amount of sodium bicarbonate was administered intravenously to restore the base deficit to normal. Following control measurements vasopressor drugs were infused intravenously by means of a constant flow pump. Studies were divided into two phases. In Phase I, 42 experiments were performed on 15 animals. Drug infusion rates, expressed aŝ gAg/min, were adrenaline, 2.5; metaraminol 25; ephedrine 250; and phenylephrine 25. We had previously determined that these doses would produce a twofold increase in MAP within a 2-3-min period. Drug infusions were continued until two or more premature ventricular contractions (PVC) occurred within 5 min, or if no PVC occurred, until MAP reached approximately 175 mm Hg. This level of hypertension was selected arbitrarily, since in most animals it presented a MAP approximately equal to twice the control value. In addition to PVC, records were examined for the incidence of supraventricular arrhythmia. After termination of drug infusions, animals were observed for the development of arrhythmia for at least 15 min. Only one drug was infused in any one experiment, and experiments were separated by intervals ranging from 4 to 7 days. In each vasopressor group at least 5 animals were studied with both anaesthetics. Two animals in the adrenaline group developed ventricular fibrillation, and were not salvaged.
In Phase II, 35 experiments were performed on 16 animals. These dogs included 10 of the animals used in Phase I. Since the use of an arbitrarilydefined therapeutic dose of vasopressor in Phase I was associated with the production of arrhythmias in only half the drug groups studied, the infusion rates of some drugs were increased in an attempt to elicit a greater incidence of cardiac arrhythmias. Drug infusion rates for ephedrine and phenylephrine were 1,000 and 50 //g/kg/min, respectively, with each anaesthetic. In the isoflurane group, the adrenaline infusion rate was increased to 10 /xg/kg/min, while adrenaline and metaraminol infusion rates in the remaining groups were the same as used in Phase I. Drug infusions were continued until two or more PVCs occurred, or if no arrhythmia occurred, until MAP reached a plateau and showed no further increase for a 3-min period. Vasopressor dose was calculated as a function of this time. Five new animals were used in the adrenaline group. Since all 5 halothane dogs in Phase I developed arrhythmias during metaraminol infusion, these studies were not repeated. However, these same animals were studied with isoflurane in Phase II metaraminol studies. In the phenylephrine and ephedrine groups, only 1 and 2 animals, respectively, were studied with both anaesthetics. A total of 8 dogs were studied in more than one vasopressor group.
In eight of the phenylephrine experiments either propranolol (0.05 mg/kg) or phentolamine (0.2 mg/kg) were administered after the development of PVC to evaluate possible mechanisms involved in the production of the vasopressor-induced arrhythmias. Frequencies of responses were analysed by the calculation of binomial distribution and other data with Student's i-test (paired where appropriate). I (table II) , a significant difference in the incidence of PVC was observed with halothane in the adrenaline (P<0.01) and metaraminol group (P<0.05) as compared with isoflurane. While no ventricular arrhythmias were induced with adrenaline during isoflurane anaesthesia, PVC were observed in all 7 of the animals that received adrenaline during halothane anaesthesia. In addition, 4 of the halothane dogs in this group developed ventricular tachycardia, and 2 progressed to ventricular fibrillation. PVC also were seen in the ephedrine groups with both halothane and isoflurane. However, there was no significant difference in the incidence of PVC between the two groups. Significant changes (P<0.05) in heart rate (43% decrease from control) were observed only with phenylephrine with each anaesthetic drug and with ephedrine (22% decrease from control) only during isoflurane anaesthesia. Infusions of adrenaline, metaraminol, and phenylephrine in Phase II produced PVC with both anaesthetics in all animals. However, only 60% of dogs given ephedrine developed PVC (table III) . Vasopressor dosage, MAP, and per cent increase in MAP were significantly higher (P<0.001) with isoflurane than with halothane for adrenaline, metaraminol, and phenylephrine, but not for ephedrine. Resultant changes in heart rates were variable; only with ephedrine during halothane anaesthesia was a significant increase (P<0.05) in heart rate observed.
RESULTS

Control values for blood-gases
The administration of propranolol to 2 isoflurane and 3 halothane animals abolished the arrhythmias. The use of phentolamine, in 3 isoflurane-phenylephrine experiments, did not terminate arrhythmias, although MAP decreased by an average of 67 mm Hg.
DISCUSSION
The interaction between inhalation anaesthetic agents and adrenergic drugs, and the production of cardiac arrhythmias, has been studied since Oliver and Schaefer (1895) first showed that adrenal extract produced ventricular fibrillation in a dog anaesthetized with chloroform. Meek, Hathaway and Orth (1937) first suggested that anaesthetics might affect the normal pacemaker to allow the development of ectopic foci. Subsequent electrophysiologic studies have shown that anaesthetic agents may shorten phase four depolarization and have direct effects on the sinoatrial node (Smith et al., 1962; Hauswirth and Schaer, 1967) . Some catecholamines have been shown to increase the automaticity of myocardial fibres (Katz and Epstein, 1968) . The effect of altered arterial blood pressure also may have an important role in the production of cardiac arrhythmias. Moe et al. (1948) and Dresel, McCannell and Nickerson (1960) reported that the production of sudden increases or decreases in aortic pressure could significantly affect the incidence of adrenaline-induced arrhythmias. Murphy, Crumpton and Meek (1949) , however, found that adrenalineinduced arrhythmias during cyclopropane anaesthesia could be produced in normotensive dogs. Katz (1965) showed that isoprenaline produced cardiac arrhythmias in cats with a decreased arterial pressure and that aortic constriction facilitated arrhythmogenicity. The relation of anaesthetic and adrenergic agents and increased arterial pressure on myocardial automaticity is supported by others (Katz and Epstein, 1968) .
Our data show that when adrenaline or metaraminol is administered, there will be a greater incidence of arrhythmias with halothane than with isoflurane. The arrhythmic dose of adrenaline during halothane anaesthesia is similar to that reported by Joas and Stevens (1971) . No comparable data for metaraminol are available. Our findings of a lower incidence of arrhythmias with ephedrine and phenylephrine during halothane anaesthesia are in agreement with others (Catenacci et al., 1963; Mclntyre, 1965; Condon, 1965) . Stevens et al. (1971) have shown that isoflurane and halothane produce similar effects on arterial pressure. The observation of the greater arrhythmogenicity of adrenaline and metaraminol during halothane than during isoflurane anaesthesia suggests that this effect may be related to differences of anaesthetic drug actions on the myocardium as opposed solely to the effects of an elevated MAP.
Ephedrine produced an arrhythmia in only 2 of 5 dogs with halothane, and in only 1 of 5 dogs with isoflurane. The level of MAP in both groups was significantly (P<0.01) greater than the pressure at which arrhythmias occurred with adrenaline and metaraminol. It may be that ephedrine, although it is generally thought to have a myocardial action, does so in some way that has less effect on automaticity than the other drugs, even in very large doses (as much as 150 mg in a 16 kg dog).
While phenylephrine did not produce ventricular arrhythmias in Phase I, it did produce PVC in every animal studied in Phase II. Very large doses of phenylephrine, given during halothane anaesthesia, have been shown to produce ventricular arrhythmias (Loehning and Czorny, 1960) , which suggests that phenylephrine has a myocardial effect in addition to its well-accepted peripheral action. The higher MAP at which arrhythmias occurred in Phase II also indicates that the pressure level, per se, is not the only factor in the production of adrenergic druginduced arrhythmias during anaesthesia. While the work of Hashimoto and Hashimoto (1972) suggests heart rate to be an important mechanism, their results obtained from vagotomized, barbituratetreated animals are difficult to reconcile with our findings. The action of propranolol on abolition of phenylephrine-induced arrhythmias, without a significant reduction in MAP, also suggests that this vasopressor may possess some beta-adrenergic effect. Although, Lucchesi (1964) and Morales-Aguilera and Williams (1965) have pointed out that propranolol in sufficient dosage, also possesses significant membrane effects. However, the dose of propranolol which we used is relatively small so that it is unlikely that the effect was the result of any action other than beta-receptor blockade.
Our findings suggest that with increased circulating adrenaline concentrations, the incidence of cardiac arrhythmias will be less with isoflurane than with halothane anaesthesia. They also suggest that, when a vasopressor agent must be used during isoflurane or halothane anaesthesia, drugs such as ephedrine or phenylephrine may be associated with fewer arrhythmias than adrenaline or metaraminol. However, the arrhythmogenic action of all drugs tested was dose dependent, and although phenylephrine did not produce PVC in every instance (Phase I), it also should be used with caution when administered in combination with anaesthetic agents which may "sensitize" the myocardium.
